Morphic Holding, Inc. - Common Stock (MORF)

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. (“Morphic”) (NASDAQMORF) and Eli Lilly and Company (“Eli Lilly”) NYSE: LLYNYSELLY)

NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. (“Morphic”) (NASDAQMORF) and Eli Lilly and Company (“Eli Lilly”) NYSE: LLYNYSELLY)

NEW YORK, July 27, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

NEW YORK, July 20, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Morphic Holding, Inc. (NasdaqGM: MORF) to Eli Lilly and Company (NYSELLY). Under the terms of the proposed transaction, shareholders of Morphic will receive $57.00 in cash for each share of Morphic that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

NEW YORK, July 10, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Morphic Holding, Inc. (NasdaqGM: MORF) to Eli Lilly and Company (NYSELLY). Under the terms of the proposed transaction, shareholders of Morphic will receive $57.00 in cash for each share of Morphic that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

Eli Lilly and Company ( NYSELLY ), a global leader in the pharmaceutical industry, on July 8, 2024, announced the completion of a definitive agreement to acquire Morphic Therapeutic, Inc. NASDAQ: MORFNASDAQMORF)

NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

BALA CYNWYD, Pa., July 08, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Morphic Holding, Inc. (NASDAQMORF) to Eli Lilly and Company for $57.00 per share in cash is fair to Morphic shareholders.

WALTHAM, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of its management team will take part in a fireside chat at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5th, at 10:30 AM ET.

-α4β7 Inhibition Rapidly Increases the Rolling Velocity and Flux of B Cells in Gut-associated Lymphoid Tissues-

WALTHAM, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Dr. Marc Schegerin, COO and CFO, will take part in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on Wednesday, May 15th, at 9:00 AM ET.

- Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis-

Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Morphic Holding, Inc. (“Morphic” or “the Company”) (NASDAQMORF). Investors who purchased Morphic securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/morf.

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Morphic Holding, Inc. (“Morphic” or “the Company”) (NASDAQMORF). Investors who purchased Morphic securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/morf.

NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- Abraham, Fruchter & Twersky, LLP (https://aftlaw.com/), a nationally recognized law firm that focuses on protecting investors’ rights, is investigating whether Morphic Holding, Inc. (NASDAQMORF), a biopharmaceutical company, violated U.S. federal securities laws by making false or misleading statements or failing to timely disclose material information to investors.

Experienced Clinical Development Leader with Deep Experience in Immunology and Inflammatory Diseases

WALTHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced its participation at investor conferences during the month of March.

-Reported positive results from EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis (UC)-